When the FDA approved the treatment in December, data showed rebounds were rare, happening among 1 to 2 percent of its study participants.
After high-ranking people including President Joe Biden and Anthony Fauci, MD, had rebounds after taking Paxlovid, some researchers have said five days — the regimen’s recommended regimen — is too short. A recent study from the National Institutes of Health seems to disprove this theory.
A research letter published Oct. 27 in JAMA found that among 158 study participants, rebounds occurred among people who took Paxlovid and those who took a placebo.
“I hope this can help people to be less afraid of a potential rebound,” David Smith, MD, the study’s lead author and an infectious disease specialist at UC San Diego Health, told The New York Times. “Symptom return is common […] It doesn’t mean that things are going south. It’s just the natural way the disease goes.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.